Publication
Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.
Kosei Hasegawa, Nicoletta Colombo, Krishnansu S Tewari, Coraline Dubot, M Valeria Cáceres, Domenica Lorusso, Ronnie Shapira-Frommer, Pamela Salman, Eduardo Yañez, Mahmut Gümüs, Mivael Olivera Hurtado de Mendoza, Vanessa Samouëlian, Vincent Castonguay, Alexander Arkhipov, Cumhur Tekin, Erin Jensen, Sarper Toker, Bradley J Monk
- Source
- PubMed
- Retrieved
- Sep 15, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260915-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
IMPORTANCE: In the KEYNOTE-826 study, pembrolizumab (vs placebo) plus platinum-based chemotherapy (with or without bevacizumab) significantly improved progression-free survival and overall survival in participants with previously untreated persistent, recurrent, or metastatic cervical cancer at…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT03635567registry_reference1.00
Candidate 1
- cancerMalignant Cervical Neoplasmdictionary0.60
Registered trialsNCT03635567
Curated evidence
Evidence citing this paper (0)
Data not yet available